ClinConnect ClinConnect Logo
Search / Trial NCT06741475

Feasibility Study of Caregiver-Assist Strategy Training

Launched by TAIPEI MEDICAL UNIVERSITY · Dec 18, 2024

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Stroke Rehabilitation Caregiver Strategy Training Activity Function

ClinConnect Summary

This clinical trial, called the Caregiver-Assist Strategy Training (CaST) study, is exploring a new way to help people who have had a stroke improve their daily activities. The main goal is to see if the CaST program is acceptable and beneficial for stroke survivors who have some difficulty with daily tasks. Researchers will compare this program to a standard education program to determine how effective CaST is in helping participants regain their functional abilities.

To participate, individuals should be aged between 65 and 74, have experienced an ischemic or hemorrhagic stroke (which are two types of strokes), and have a caregiver who can help them. Participants will attend 10 sessions of either the CaST program or the education program, meeting 1 to 2 times a week. They will be evaluated at different points: before starting, right after completing the program, and again at 3 and 6 months later. Additionally, each participant will have a conversation with researchers after their sessions to share their experiences. This trial is currently recruiting participants and aims to make a positive impact on the lives of stroke survivors and their caregivers.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Being willing to provide informed consent
  • Diagnosis with ischemic and/or hemorrhagic stroke
  • Modified Rankin Scale (mRS) ranges from 2 to 4
  • Rehabilitation frequency less than 3 days per week
  • Having a healthy caregiver
  • Exclusion Criteria:
  • Undergoing palliative care
  • Major diseases or severe conditions influencing study participation, such as global aphasia, dementia, multiple organ failure, immobilization due to fracture, etc Moderate post-stroke cognitive impairment, with Montreal Cognitive Assessment score \<22
  • Pre-stroke mRS \> 1
  • Participating in other interventional study concurrently.

About Taipei Medical University

Taipei Medical University (TMU) is a leading educational and research institution located in Taipei, Taiwan, dedicated to advancing health sciences and clinical research. Established with a focus on fostering innovation in medical education, TMU integrates comprehensive clinical training with rigorous research methodologies. The university is committed to improving patient outcomes through a strong emphasis on translational medicine and interdisciplinary collaboration. TMU's clinical trial initiatives are designed to explore new treatments and therapies, contributing to the global body of medical knowledge while adhering to the highest ethical standards and regulatory compliance.

Locations

Taipei City, , Taiwan

New Taipei City, , Taiwan

Taipei City, , Taiwan

Patients applied

0 patients applied

Trial Officials

Feng-Heng Chang, ScD

Principal Investigator

Graduate Institute of Injury Prevention and Control, Taipei Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported